



**Novelix Pharmaceuticals limited**

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956  
(NOVELIX | 536565 | INE314I01036)

## NOTICE OF THE EXTRA ORDINARY GENERAL MEETING

Notice is hereby given that the Extra Ordinary General Meeting (“EGM”) of the members of NOVELIX PHARMACEUTICALS LIMITED (formerly known as Trimurthi Limited) will be held on Wednesday, July 01, 2026, at 3.30 P.M. through Video Conferencing (“VC”)/Other Audio-Visual Means (OAVM) to transact the following businesses:

### SPECIAL BUSINESS:

#### Item No. 1: Issue of Equity Shares on Preferential basis

To consider and if thought fit, to pass with or without modification(s), the following resolution as **Special Resolution**:

“**RESOLVED THAT** pursuant to provisions of Sections 42, 62 and other applicable provisions, if any, of the Companies Act, 2013, (including any statutory modification or re-enactment thereof for the time being in force) read with the Companies (Prospectus and Allotment of Securities) Rules, 2014 and the Companies (Share Capital and Debentures) Rules, 2014 (including any statutory modification or re-enactment thereof for the time being in force), Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended (“**SEBI (ICDR) Regulations, 2018**”), the Securities and Exchange Board of India (Substantial Acquisitions of Shares and Takeovers) Regulations, 2011, as amended (“**Takeover Regulations**”), the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and the rules, regulations, notifications and circulars issued thereunder and other applicable law including any other rules, regulations, guidelines, notifications, circulars and clarifications issued thereon from time to time by the Government of India, the Securities and Exchange Board of India (“**SEBI**”), Reserve Bank of India (“**RBI**”), the Ministry of Corporate Affairs, the respective stock exchanges where the equity shares of the Company are listed (“**Stock Exchanges**”), and or any other competent regulatory authority and in accordance with the uniform listing agreements entered into with the Stock Exchanges and in accordance with the enabling provisions of the Memorandum of Association and Articles of Association of the Company and subject to such approvals, consents, permissions and sanctions as may be necessary or required from regulatory or other appropriate authorities, including but not limited to the Stock Exchanges and SEBI and subject to such conditions and modifications as may be prescribed, stipulated or imposed by any of them while granting such approval, consents, permissions and sanctions and which terms may be agreed to by the Board of Directors of the Company (hereinafter referred to as “**the Board**” which expression shall include any Committee constituted by the Board or any person(s) authorized by the Board to exercise the powers conferred on the Board by this Resolution) and subject to such terms, conditions and modifications as the Board may in its discretion impose or agree to, consent of the Members be and is hereby accorded to authorize, to create, issue, offer and allot by way of Preferential Allotment, upto 12,00,000 Equity Shares of Face Value of Rs. 10/- (Rupees Ten only) each at an Issue Price of Rs. 57/- (Rupees Fifty Seven only) (including premium of Rs. 47/- each) aggregating to Rs. 6,84,00,000/- (Rupees Six Crore Eighty Four Lakhs only) to Non-Promoters, on preferential allotment basis in compliance with Chapter V of SEBI (ICDR) Regulations, 2018 and subsequent amendments thereto & on such terms and conditions and in such manner as the Board may in its absolute discretion deem fit, to the following persons/entities as mentioned below:

### Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6<sup>th</sup> Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)

[www.trimurthidrugs.com](http://www.trimurthidrugs.com)

Sr. No.	Name of the Proposed Allottees	Category (Promoter or Promoter Group / Non Promoter)	No. of Equity Shares proposed to be allotted	Name of the Ultimate Beneficial Owner
1	SAKSHI MALANI	Non Promoter	150000	SAKSHI MALANI
2	PEDDI SRIDHAR	Non Promoter	100000	PEDDI SRIDHAR
3	PALAKURTHI RAKESH	Non Promoter	100000	PALAKURTHI RAKESH
4	RAHUL INNANI	Non Promoter	100000	RAHUL INNANI
5	SUMAN RAJIV BIHANI	Non Promoter	50000	SUMAN RAJIV BIHANI
6	VEDANT RAJIV BIHANI	Non Promoter	50000	VEDANT RAJIV BIHANI
7	PRAKASH GADLA	Non Promoter	50000	PRAKASH GADLA
8	K VARSHA	Non Promoter	50000	K VARSHA
9	VIJAYA SURESH NIMBALE	Non Promoter	25000	VIJAYA SURESH NIMBALE
10	PRASANTH SOWMITHRY BRUNDAVANAM	Non Promoter	25000	PRASANTH SOWMITHRY BRUNDAVANAM
11	T PRAVEEN KUMAR	Non Promoter	115000	T PRAVEEN KUMAR
12	ALLADI PRAVEEN	Non Promoter	50000	ALLADI PRAVEEN
13	GANGADHAR KATHURI	Non Promoter	10000	GANGADHAR KATHURI
14	RAJENDER BELIDE	Non Promoter	100000	RAJENDER BELIDE
15	BELIDE VIJAYALAKSHMI	Non Promoter	100000	BELIDE VIJAYALAKSHMI
16	VENKATRAMANA MANUSANI	Non Promoter	50000	VENKATRAMANA MANUSANI
17	MANUSANI JALAJA LAXMI	Non Promoter	50000	MANUSANI JALAJA LAXMI
18	PALLAPOTHU SIVAKRISHNA	Non Promoter	25000	PALLAPOTHU SIVAKRISHNA
	<b>TOTAL</b>		<b>12,00,000</b>	

**RESOLVED FURTHER THAT:**

- i. The Relevant Date for the purpose of pricing of issue of Equity Shares in accordance with the Regulation 161 of SEBI (ICDR) Regulations, 2018 (as amended) be fixed as 01<sup>st</sup> June, 2026 to consider the proposed preferential issue of Equity Shares.
- ii. The Equity Shares as may be offered, issued, and allotted in accordance with the terms of this resolution, shall be in dematerialised form.
- iii. The Equity Shares to be allotted shall rank pari passu in all respects with the existing Equity Shares of the Company, including dividend.
- iv. The Equity Shares shall be issued and allotted by the Company to the Proposed Allottees within a period of 15 days from the date of passing of this special resolution provided that where any approval or permission by any regulatory authority or the Central Government or the Stock Exchanges is pending, the allotment shall be completed within a period of 15

days from the date of such approval or permission, as the case may be in compliance with Regulation 170 of the SEBI (ICDR) Regulations, 2018.

**RESOLVED FURTHER THAT** the Equity Shares to be offered, issued and allotted shall be subject to lock in for such periods as prescribed in Regulation 167 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

**RESOLVED FURTHER THAT** the Equity Shares to be so created, offered, issued and allotted shall be subject to the provisions of the Memorandum and Articles of Association of the Company.

**RESOLVED FURTHER THAT** subject to the SEBI (ICDR) Regulations, 2018 and other applicable laws the Board be and is hereby authorized to decide and approve the other terms and conditions of the issue of the above-mentioned Equity Shares and to vary, modify or alter the terms and conditions and size of the issue, as it may deem expedient, without being required to seek any further consent or approval of the Company in a General Meeting.

**RESOLVED FURTHER THAT** the Board be and is hereby authorized to accept any modifications in the proposal as may be required by the agencies involved in such issues but subject to such conditions as the Reserve Bank of India (RBI) / Securities and Exchange Board of India (SEBI) and/ or such other appropriate authority may impose at the time of their approval as agreed by the Board.

**RESOLVED FURTHER THAT** for the purpose of giving effect to this resolution, the Board be and is hereby authorized on behalf of the Company to take all such actions and do all such deeds, matters and things as it may, in its absolute discretion, deem necessary, desirable or expedient and to settle any question, difficulties or doubts that may arise in this regard including but not limited to the offering, issue and allotment of Equity Shares of the Company as it may in its absolute discretion deem fit and proper.

**RESOLVED FURTHER THAT** Mr. Venkateshwarlu Pulluru (DIN: 02076871), Whole-time director of the Company or Mr. Gnana Prakash Gattu (DIN: 00517921), Director of the Company or Ms. Nishita Kalantri, Company Secretary and Compliance Officer of the Company be and is hereby severally authorized to do all such act (s), deed(s) and things including all forms, documents, filing with Ministry of Corporate Affairs/ Registrar of Companies, Stock Exchange, Depositories or any other agency as may be necessary and incidental to give effect to the aforesaid Resolution.

**RESOLVED FURTHER THAT** the Board be and is hereby authorized to delegate all or any of the powers herein conferred by this resolution to any Director or Directors or to any Committee of Directors or to any Officer or Officers of the Company to give effect to this resolution including execution of any documents on behalf of the Company and to represent the Company before any governmental or regulatory authorities and to appoint any professional advisors, consultants, advocates and advisors to give effect to this resolution and further to take all others steps which may be incidental, consequential, relevant or ancillary in this connection.”

**By the order of the Board of Directors  
For Novelix Pharmaceuticals Limited**

**Date: 04<sup>th</sup> June, 2026  
Place: Hyderabad**

**Sd/-  
Venkateshwarlu Pulluru  
(Whole Time Director)  
DIN: 02076871**

## Notes:

1. The Extra Ordinary General Meeting (“EGM”) will be held on Wednesday, July 01, 2026, at 3.30 P.M. through Video Conferencing (VC)/ Other Audio Visual Means (OAVM) in compliance with the applicable provisions of the Companies Act, 2013 read with MCA General Circular No. 14/2020 dated 08<sup>th</sup> May, 2020, MCA General Circular No. 17/2020 dated 13<sup>th</sup> April, 2020 and 20/2020 dated 5<sup>th</sup> May, 2020 , 02/2021 dated 13<sup>th</sup> January, 2021, 03/2022 dated 5<sup>th</sup> May, 2022, 10/2022 dated 28<sup>th</sup> December, 2022, 11/2022 dated 28 December, 2022, 09/2023 dated 25<sup>th</sup> September, 2023, 09/2024 dated 19<sup>th</sup> September, 2024 and General Circular No. 03/2025 dated 22<sup>nd</sup> September, 2025 and SEBI circular SEBI Circular dated 12 May, 2020, SEBI Circular dated 15 January, 2021, 13 May 2022, 05 January 2023, 03 October 2024.
2. The EGM of the Company is being held through VC / OAVM. The deemed venue for the EGM shall be the Registered Office of the Company situated at H No: 3-6-237/610, Flat No: 610, 6Th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029.
3. Pursuant to the provisions of the Act, a member entitled to attend and vote at the EGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. Since this EGM is being held pursuant to the MCA Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the EGM and hence the Proxy Form and Attendance Slip are not annexed to this Notice.
4. However, the Body Corporates are entitled to appoint authorized representatives to attend the EGM through VC/OAVM and participate there at and cast their votes through e-voting. Body Corporates whose authorized representatives are intending to attend the Meeting through VC/OAVM are requested to send, a certified copy of the Board Resolution authorizing their representative to attend and vote on their behalf at the Meeting and through E-voting at [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com).
5. Members attending the EGM through VC / OAVM shall be counted for the purpose of reckoning the quorum under Section 103 of the Act.
6. An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 relating to the Special Business to be transacted at the Extraordinary General Meeting is annexed hereto.
7. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in electronic form are therefore requested to submit the PAN to their Depository Participants with whom they are maintaining their demat accounts. Members holding shares in physical form can submit their PAN details to the Company or to the Registrar and Share Transfer Agent.
8. Members who wish to inspect the Register of Directors and Key Managerial Personnel and their shareholding maintained under section 170 of Companies Act, 2013 and Register of Contracts or arrangements in which directors are interested maintained under section 189

of the Companies Act, 2013 and Relevant documents referred to in this Notice of EGM and explanatory statement on the date of EGM in electronic mode can send an email to [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com).

9. The business set out in the Notice will be transacted through electronic voting system and the Company is providing facility for voting by electronic means. Instructions and other information relating to e-voting are given in this Notice.
10. In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the EGM.
11. The Notice of EGM will be placed on the Company's website [www.novelixpharma.com](http://www.novelixpharma.com).
12. Members are requested to intimate changes, if any, pertaining to their name, postal address, email address, telephone/ mobile numbers, Permanent Account Number (PAN), mandates, nominations, power of attorney, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc., to their Depository Participant in case the shares are held in electronic form and to M/s. Venture Capital & Corporate Investments Private Limited (Registrar and Share Transfer Agent) at 12-10-167, Bharatnagar, Hyderabad- 500018, Telangana,; e-mail: [info@vccilindia.com](mailto:info@vccilindia.com) in case the shares are held in physical form.
13. Members are requested to quote their Folio No. or DP ID / Client ID, in case shares are in physical / dematerialized form, as the case may be, in all correspondence with the Company / Registrar and Share Transfer Agent.
14. Shareholders of the Company holding shares either in physical form or in Dematerialized forms as on Benpos date i.e., 05<sup>th</sup> June, 2026 will receive the Notice of EGM through electronic mode only pursuant to General circular No. 1712020 dated 13 April, 2020.
15. Electronic copy of the EGM Notice is being sent to all the members whose e-mail addresses are registered with the Company/Depository Participant(s)/ Registrar and Share Transfer Agent of the Company for communication purposes. In case any member is desirous of obtaining hard copy of the EGM Notice, may send request to the Company's e-mail address at [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com) mentioning Folio No./ DP ID and Client ID.
16. Information and other instructions relating to e-voting are as under:
  - a. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the EGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized e-Voting's agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the EGM will be provided by CDSL.
  - b. The Members can join the EGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure

mentioned in the Notice. The facility of participation at the EGM through VC/OAVM will be made available to at least 1000 members on first come first served basis.

- c. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the EGM without restriction on account of first come first served basis.
- d. The Company has engaged the services of Central Depository Services Limited (“CDSL”) as the Agency to provide e-voting facility.
- e. The Board of Directors of the Company at their meeting held on 04<sup>th</sup> June, 2026 has appointed Mr. Bharat Khaniwal, (Membership No.: ACS-29035) Proprietor of M/s Bharat Khaniwal & Co., Practicing Company Secretary, Jaipur, as the Scrutinizer, to scrutinize the e-voting during the EGM and remote e-voting process prior to EGM in a fair and transparent manner and they have communicated their willingness to be appointed and will be available for same purpose.
- f. Voting rights shall be reckoned on the paid-up value of shares registered in the name of the member/beneficial owner as on the cut-off date i.e., **June 24, 2026**.
- g. The Scrutinizer, after scrutinizing e-voting at the EGM and remote e-voting, will not later than 2 working days of conclusion of the Meeting, make a consolidated scrutinizer’s report and submit the same to the Chairman. The results declared along with the consolidated scrutinizer’s report shall be placed on the website of the Company [www.novelixpharma.com](http://www.novelixpharma.com). The results shall simultaneously be communicated to the Stock Exchange where the shares of the Company are listed.
- h. Subject to receipt of requisite number of votes, the Resolutions shall be deemed to be passed on the date of the Meeting, i.e., July 01, 2026.
- i. Once the vote on a resolution is cast by a member, the member shall not be allowed to change it subsequently or cast the vote again.

## **17. THE INTRUCTIONS OF SHAREHOLDERS FOR E-VOTING AND JOINING VIRTUAL MEETINGS ARE AS UNDER:**

**Step 1: Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.**

**Step 2: Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.**

- i. The voting period begins on 28<sup>th</sup> June 2026 at 09:00 A.M. IST and ends on 30<sup>th</sup> June 2026 at 05:00 PM IST During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the **cut-off date (record date) 24<sup>th</sup> June 2026** may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.

- ii. Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- iii. Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

**Step 1: Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.**

- iv. In terms of SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to abovesaid SEBI Circular, Login method for e-Voting and joining virtual meetings **for Individual shareholders holding securities in Demat mode CDSL/NSDL** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with <b>CDSL Depository</b>	<p>Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are <a href="https://web.cdslindia.com/myeasi/home/login">https://web.cdslindia.com/myeasi/home/login</a> or visit <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on Login icon and select New System Myeasi Tab.</p> <p>After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p>

	<p>Additionally, there is also links provided to access the system of all e-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME, so that the user can visit the e-Voting service providers’ website directly.</p> <p>If the user is not registered for Easi/Easiest, option to register is available at <a href="https://web.cdslindia.com/myeasi/Registration/EasiRegistration">https://web.cdslindia.com/myeasi/Registration/EasiRegistration</a></p> <p>Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page or click on <a href="https://evoting.cdslindia.com/Evoting/EvotingLogin">https://evoting.cdslindia.com/Evoting/EvotingLogin</a> The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the e-voting is in progress and also able to directly access the system of all e-Voting Service Providers.</p>
<p>Individual Shareholders holding securities in demat mode with NSDL Depository</p>	<p>If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a> either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p> <p>If the user is not registered for IDeAS e-Services, option to register is available at <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a>. Select “Register Online for IDeAS “Portal or click at <a href="https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</a></p> <p>Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsdl.com/">https://www.evoting.nsdl.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen-digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p>
<p>Individual Shareholders (holding securities</p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-</p>

in demat mode) login through their <b>Depository Participants (DP)</b>	Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
--	--

**Important note:** Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

**Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL**

<b>Login type</b>	<b>Helpdesk details</b>
Individual Shareholders holding securities in Demat mode with <b>CDSL</b>	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at toll free no. 1800 22 55 33
Individual Shareholders holding securities in Demat mode with <b>NSDL</b>	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.co.in">evoting@nsdl.co.in</a> or call at toll free no.: 1800 1020 990 and 1800 22 44 30

**Step 2 :** Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

(i) Login method for e-Voting and joining virtual meetings for **Physical shareholders and shareholders other than individual holding in Demat form.**

- 1) The shareholders should log on to the e-voting website [www.evotingindia.com](http://www.evotingindia.com).
- 2) Click on “Shareholders” module.
- 3) Now enter your User ID
  - a. For CDSL: 16 digits beneficiary ID,
  - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
  - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to [www.evotingindia.com](http://www.evotingindia.com) and voted on an earlier e-voting of any company, then your existing password is to be used.

6) If you are a first-time user follow the steps given below:

	<b>For Physical shareholders and other than individual shareholders holding shares in Demat.</b>
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details <b>OR</b> Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.

- (ii) After entering these details appropriately, click on “SUBMIT” tab.
- (iii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (iv) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (v) Click on the EVSN for the **(Company Name)** on which you choose to vote.
- (vi) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (vii) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.

- (viii) After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (ix) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (x) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xi) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xii) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.
- (xiii) **Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.**
- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to [www.evotingindia.com](http://www.evotingindia.com) and register themselves in the “Corporates” module.
  - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com).
  - After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
  - The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
  - It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
  - Alternatively non-individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com) (designated email address by company), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

**18. INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM/EGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:**

1. The procedure for attending meeting & e-Voting on the day of the AGM/ EGM is same as the instructions mentioned above for e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM/EGM.
4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least 3 (Three) days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance 3 (Three) days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com)). These queries will be replied to by the company suitably by email.
8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
9. Only those shareholders, who are present in the AGM/EGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the EGM/AGM.
10. If any Votes are cast by the shareholders through the e-voting available during the EGM/AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders may be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

## **1. Other Guidelines for Members**

- a. The voting rights of Members shall be in proportion to their share in the paid-up equity share capital of the Company as on the **cut-off date of Wednesday, 24<sup>th</sup> June, 2026.**

- b. A person, whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of remote e-Voting or casting vote through e-Voting system during the meeting.
  - c. The Scrutinizer shall after the conclusion of e-Voting at the EGM, first download the votes cast at the EGM and thereafter unblock the votes cast through remote e-Voting and shall make a consolidated scrutinizer's report of the total votes cast in favor or against, invalid votes, if any, and whether the resolution has been carried or not, and such Report shall then be sent to the Chairman or a person authorized by him, within 48 (forty eight) hours from the conclusion of EGM, who shall then countersign and declare the result of the voting forthwith. The Results declared along with the report of the Scrutinizer shall be placed on the website of the Company at [www.novelixpharma.com](http://www.novelixpharma.com) and on the website of CDSL at <https://www.evotingindia.com/> immediately after the declaration of Results by the Chairman or a person authorized by him. The results shall also be immediately forwarded to the Stock Exchange i.e. "The BSE Limited" ("BSE").
2. Pursuant to the MCA Circulars and SEBI Circular, in view of the prevailing situation, owing to the difficulties involved in dispatching of physical copies of the Notice of the EGM is being sent only by email to the Members. Therefore, those Members, whose email address is not registered with the Company or with their respective Depository Participant/s, and who wish to receive the Notice of the EGM and all other communication sent by the Company, from time to time, can get their email address registered with the Company / RTA or respective Depository Participant(s) (DP)

#### **19. PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.**

For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to **Company mail id: [novelixpharmaceuticals@gmail.com](mailto:novelixpharmaceuticals@gmail.com) /RTA email id: [info@vccilindia.com](mailto:info@vccilindia.com).**

1. For Demat shareholders -, Please update your email id & mobile no. with your respective **Depository Participant (DP)**
  2. For Individual Demat shareholders – Please update your email id & mobile no. with your respective **Depository Participant (DP)** which is mandatory while e-Voting & joining virtual meetings through Depository.
20. If you have any queries or issues regarding attending EGM & e-Voting from the CDSL e-Voting System, you can write an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or contact at toll free no. 1800 22 55 33
  21. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL, ) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower

Parel (East), Mumbai - 400013 or send an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or call toll free no. 1800 22 55 33.

22. The Company has sent individual letters to all the Members holding shares of the Company in physical form for furnishing their PAN, KYC details and Nomination pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD\_RTAMB/P/CIR/2021/655 dated November 3, 2021 in Form ISR-1. The Form ISR-1 is also available on the website of the Company at [www.novelixpharma.com](http://www.novelixpharma.com) The Attention of the Members holding shares of the Company in physical form is invited to go through and submit the said Form ISR-1.
23. Members are requested to intimate changes, if any, pertaining to their name, postal address, e-mail address, telephone/mobile numbers, PAN, registering of nomination, power of attorney registration, Bank Mandate details, etc., to their DPs in case the shares are held in electronic form and to the RTA in prescribed Form ISR-1 and other forms pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD\_RTAMB/P/CIR/2021/655 dated November 3, 2021. Further, Members may note that SEBI has mandated the submission of PAN by every participant in securities market.
24. Nomination facility: As per the provisions of Section 72 of the Act, the facility for making nomination is available to the Members in respect of the shares held by them. Members who have not yet registered their nomination are requested to register the same by submitting Form No. SH-13. If a member desires to opt-out or cancel the earlier nomination and record a fresh nomination, the Member may submit the same in Form ISR-3 or Form SH-14, as the case may be. The said forms can be downloaded from the Company's website at [www.novelixpharma.com](http://www.novelixpharma.com) in Members are requested to submit the said form to their DPs in case the shares are held in electronic form and to the RTA at [www.vccipl.com](http://www.vccipl.com) in case the shares are held in physical form, quoting their folio no(s).
25. In terms of the Listing Regulations, securities of listed companies can only be transferred in dematerialized form with effect from 1<sup>st</sup> April 2019. In view of the above, Members are advised to dematerialize shares held by them in physical form.
26. Electronic copy of all the documents referred to in the accompanying Notice of the EGM and the Explanatory Statement shall be available for inspection at the website of the Company at [www.novelixpharma.com](http://www.novelixpharma.com) .
27. Details as required in sub-regulation (3) of Regulation 36 of the Listing Regulations and Secretarial Standard on General Meeting (SS-2) of ICSI, in respect of the Directors seeking appointment/ re-appointment at the EGM, forms integral part of the Notice of the EGM. Requisite declarations have been received from the Directors for seeking appointment/ re-appointment.
28. Since the EGM will be held through VC/OAVM Facility, the Route Map is not annexed in this Notice.

**By the order of the Board of Directors  
For Novelix Pharmaceuticals Limited**

**Date: 04<sup>th</sup> June, 2026  
Place: Hyderabad**

**Sd/-  
Venkateshwarlu Pulluru  
(Whole Time Director)  
DIN: 02076871**

## EXPLANATORY STATEMENT IN RESPECT OF THE SPECIAL BUSINESS PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

The following Statement sets out all material facts relating to the Special Business mentioned in the accompanying Notice:

### Item No. 1- Issue of Equity Shares on Preferential basis

The Board of the Directors of the Company at its meeting held on 04<sup>th</sup> June, 2026 has given their consent subject to approval of Members by way of Special Resolution to issue 12,00,000 Equity Shares to Non-Promoters on Preferential Allotment basis.

In terms of Section 62(1)(c) read with Sections 42 of the Companies Act, 2013 and rules made thereunder (“Act”), and in accordance with the provisions of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“ICDR Regulations”) as amended, and on the terms and conditions and formalities as stipulated in the Act and the ICDR Regulations, the Preferential Issue requires approval of the shareholders of the Company by way of a special resolution.

Accordingly, consent of the members is being sought in terms of Section 42 & 62 of the Companies Act 2013 and Chapter V of the SEBI (ICDR) Regulations, 2018.

The details of the issue and other particulars as required in terms of Regulation 163 of the Chapter V of the SEBI (ICDR) Regulations, 2018, Rule 13 of Companies (Share Capital and Debentures) Rules, 2014 and Rule 14 of Companies (Prospectus and allotment of securities) Rules, 2014 in relation to the above said Special Resolution are given as under.

#### 1. List of Allottees for Preferential Allotment of Equity Shares:

Sr. No.	Name of the Proposed Allottees	Category (Promoter or Promoter Group / Non Promoter)	No. of Equity Shares proposed to be allotted	Name of the Ultimate Beneficial Owner
1	SAKSHI MALANI	Non Promoter	150000	SAKSHI MALANI
2	PEDDI SRIDHAR	Non Promoter	100000	PEDDI SRIDHAR
3	PALAKURTHI RAKESH	Non Promoter	100000	PALAKURTHI RAKESH
4	RAHUL INNANI	Non Promoter	100000	RAHUL INNANI
5	SUMAN RAJIV BIHANI	Non Promoter	50000	SUMAN RAJIV BIHANI
6	VEDANT RAJIV BIHANI	Non Promoter	50000	VEDANT RAJIV BIHANI
7	PRAKASH GADLA	Non Promoter	50000	PRAKASH GADLA
8	K VARSHA	Non Promoter	50000	K VARSHA
9	VIJAYA SURESH NIMBALE	Non Promoter	25000	VIJAYA SURESH NIMBALE
10	PRASANTH SOWMITHRY BRUNDAVANAM	Non Promoter	25000	PRASANTH SOWMITHRY BRUNDAVANAM
11	T PRAVEEN KUMAR	Non Promoter	115000	T PRAVEEN KUMAR
12	ALLADI PRAVEEN	Non Promoter	50000	ALLADI PRAVEEN

13	GANGADHAR KATHURI	Non Promoter	10000	GANGADHAR KATHURI
14	RAJENDER BELIDE	Non Promoter	100000	RAJENDER BELIDE
15	BELIDE VIJAYALAKSHMI	Non Promoter	100000	BELIDE VIJAYALAKSHMI
16	VENKATRAMANA MANUSANI	Non Promoter	50000	VENKATRAMANA MANUSANI
17	MANUSANI JALAJA LAXMI	Non Promoter	50000	MANUSANI JALAJA LAXMI
18	PALLAPOTHU SIVAKRISHNA	Non Promoter	25000	PALLAPOTHU SIVAKRISHNA
	<b>TOTAL</b>		<b>12,00,000</b>	

## 2. Objects of the preferential issue:

The proceeds of the proposed preferential issue of 12,00,000 Equity Shares to Non-Promoters are intended to be utilized for meeting lab-scale technology transfer expenses, essential consumables, Pre Operative Expenses and Quality Control Equipments, travelling and accommodation expenses of the technical experts engaged for technology transfer, installation and training, Deposit For Land Lease at Siddipet district, near Gajwel, Telangana and Land Development for Preparation of Micro Algae Cultivation & Glass Reactor Systems Installation.

### Broad range of proposed utilization of Issue proceeds:

Sr. No.	Particulars	Estimated Amount to be utilised Amount (Rs in Lakhs)	Tentative Timeline for Utilization of Issue Proceeds
1	Lab Scale Tech Transfer Fee to GMBU, Germany	75.00	Before 30-09-2026
2	Deposit For Land Lease	100.00	Before 30-09-2026
3	Land Development	188.00	Before 30-09-2026
4	Consumables	100.00	Before 30-09-2026
5	Travelling & Accommodation of German Tech	35.00	Before 30-09-2026
6	Pre Operative Expenses	125.00	Before 30-09-2026
7	Quality Control Equipments	61.00	Before 30-09-2026
	<b>Total</b>	<b>684.00</b>	

The amount specified for the aforementioned Objects may deviate +/- 10% depending upon the future circumstances, given that the Objects are based on management estimates and other commercial and technical factors. Accordingly, the same is dependent on a variety of factors such as financial, market and sectoral conditions, business performance and strategy, competition and other external factors, which may not be within the control of the Company and may result in modifications to the proposed schedule for utilization of the Issue Proceeds at the discretion of the Board, subject to compliance with applicable laws. If the Issue Proceeds are not utilised (in full or in part) for the Objects to any such factors, the remaining Issue Proceeds shall

be utilised to any other objects in such manner as may be determined by the Board, in accordance with applicable laws.

#### **Interim Use of Issue Proceeds**

Our Company, in accordance with the policies formulated by our Board from time to time, will have flexibility to deploy the Issue Proceeds in compliance with all the applicable laws and regulations. The said deployment shall be done in compliance with the applicable laws pending complete utilization of the Issue Proceeds for the Objects described above, our Company intends to, inter alia, invest the Issue Proceeds in money market instruments, mutual funds, deposits in scheduled commercial banks, securities issued by government of India or any other investments as permitted under applicable laws.

#### **3. Maximum number of specified securities to be issued and price of the securities:**

The resolution set out in the accompanying notice authorizes the Board to issue 12,00,000 Equity Shares of Rs. 10/- each at an Issue Price of Rs. 57/- each (including premium of Rs. 47/- each) on preferential basis for Cash consideration.

#### **4. Pricing/ Basis on which the price of the Preferential Issue has been arrived at:**

A] The Equity Shares of the Company are listed on BSE Limited ('BSE') (referred to as "Stock Exchange"). The Equity Shares of the Company are frequently traded as per Regulation 164 (5) of Chapter V of the SEBI (ICDR) Regulations, 2018. In terms of Regulation 164 (1) of Chapter V of SEBI (ICDR) Regulations, 2018, the minimum price at which equity shares shall be issued shall not be less than higher of the following:

(a) Rs. 56.68/- each- the 90 Trading days volume weighted average price of the equity shares of the Company quoted on the Stock Exchange preceding the Relevant Date; or

(b) Rs. 54.22/- each- the 10 Trading days volume weighted average price of the equity shares of the Company quoted on the Stock Exchange preceding the Relevant Date.

Pursuant to above, the minimum issue price determined in accordance with Regulations 164(1) read with Regulation 161 of Chapter V of the SEBI (ICDR) Regulations, 2018 is Rs. 56.68/- each.

B] Method of determination of price as per the Articles of Association of the Company - Not applicable as the Articles of Association of the Company does not provide for a method on the determination of a floor price/ minimum price of the shares issued on preferential basis.

In view of the above, and after considering all relevant factors, the Board of the Directors of the Company has approved the issue price of Equity Shares on Preferential basis shall be at a price of Rs. 57/- each (Face Value Rs. 10/- each + Premium Rs. 47/- each).

#### **5. Relevant date with reference to which the price has been arrived at:**

The Relevant Date in terms of Regulation 161 of SEBI (ICDR) Regulations, 2018 for determining the price of Equity Shares with reference to the proposed allotment is 01<sup>st</sup> June, 2026.

**6. The class or classes of persons to whom the allotment is proposed to be made:**

The proposed preferential allotment of Equity Shares is made to Individuals belonging to Non-Promoters category.

**7. Intention of promoters, directors or key managerial personnel or senior management of the issuer to subscribe to the offer:**

None of the existing directors, promoters or key managerial personnel or senior management of the Company have shown any intention to subscribe to proposed Preferential Issue of Equity Shares.

**8. The change in control if any in the company that would occur consequent to the preferential offer;**

The proposed Preferential Allotment of Equity Shares will not result in any change in the management and control of the Company.

**9. Time frame within which the preferential allotment shall be completed:**

As required under the Regulation 170 of SEBI (ICDR) Regulations 2018, the Company shall complete the allotment of Equity Shares within a period of 15 days from the date of passing of this Special Resolution by the shareholders in Extra Ordinary General Meeting, provided that where any approval or permission by any regulatory authority or the Central Government or the Stock Exchanges is pending, the allotment shall be completed within a period of 15 days from the date of such approval or permission.

**10. Shareholding pattern before and after Preferential Issue would be as follows:**

Category	Pre Preferential Issue*		Post Preferential Issue of 12,00,000 Equity Shares under current Preferential Issue		Post Preferential Issue (considering 12,00,000 Equity Shares under current Preferential Issue and assuming full conversion of 33,75,000 outstanding warrants allotted on 10 <sup>th</sup> January, 2025 into equity shares.)	
	No. of shares held	% of share holding	No. of shares held	% of share holding	No. of shares held	% of share holding
<b>Promoter s Holding</b>						
<b>Indian</b>						
Individual	4180733	17.50%	4180733	16.66%	5455733	19.16%
Bodies corporate	7902000	33.07%	7902000	31.49%	10002000	35.13%
Sub-total	12082733	50.57%	12082733	48.15%	15457733	54.29%

<b>Foreign Promoters</b>	-	-	-	-	-	-
<b>Sub-total (A)</b>	<b>12082733</b>	<b>50.57%</b>	<b>12082733</b>	<b>48.15%</b>	<b>15457733</b>	<b>54.29%</b>
<b>Non-promoters' holding</b>						
<b>Institutional investors</b>	-	-	-	-	-	-
<b>Non-institution</b>						
Private corporate bodies, Partnership Firm & LLP	664392	2.78%	664392	2.65%	664392	2.33%
Indian public & HUF	10987484	45.98%	12187484	48.57%	12187484	42.81%
(Others (including IEPF, NRIs, Clearing members, Trusts, etc))	160,391	0.67%	160,391	0.64%	160,391	0.56%
<b>Sub-total (B)</b>	<b>11,812,267</b>	<b>49.43%</b>	<b>13,012,267</b>	<b>51.85%</b>	<b>13,012,267</b>	<b>45.71%</b>
<b>Non Promoter &amp; Non Public</b>	-	-	-	-	-	-
<b>GRAND TOTAL</b>	<b>23,895,000</b>	<b>100.00 %</b>	<b>25,095,000</b>	<b>100.00%</b>	<b>28,470,000</b>	<b>100.00%</b>

\* As on 29<sup>th</sup> May, 2026

#### 11. Consequential Changes in the Voting Rights:

Voting rights will change according to the change in the shareholding pattern mentioned above.

#### 12. Identity of the natural persons who are the ultimate beneficial owners of the shares proposed to be allotted and/or who ultimately control the proposed allottees, the percentage of post preferential issues that may be held by them and change in control if any in the issuer consequent to the preferential issues:

Sr. No.	Name of the Proposed Allottees	Category (Promoter/ Non Promoter)	Ultimate Beneficial Owner	Pre-Preferential Issue*		No. of Equity Shares proposed to be allotted	Post Preferential Issue		
				No. of Shares held	% of share holding		No. of Shares held	% of share holding (considering 12,00,000 Equity Shares under current Preferential Issue)	% of share holding (considering 12,00,000 Equity Shares under current Preferential Issue and assuming full conversion of 33,75,000 outstanding warrants allotted on 10th January, 2025 into equity shares.)

1	SAKSHI MALANI	Non Promoter	SAKSHI MALANI	0	0.00%	150000	150000	0.60%	0.53%
2	PEDDI SRIDHAR	Non Promoter	PEDDI SRIDHAR	58399	0.24%	100000	158399	0.63%	0.56%
3	PALAKURTHI RAKESH	Non Promoter	PALAKURTHI RAKESH	574110	2.40%	100000	674110	2.69%	2.37%
4	RAHUL INNANI	Non Promoter	RAHUL INNANI	0	0.00%	100000	100000	0.40%	0.35%
5	SUMAN RAJIV BIHANI	Non Promoter	SUMAN RAJIV BIHANI	40000	0.17%	50000	90000	0.36%	0.32%
6	VEDANT RAJIV BIHANI	Non Promoter	VEDANT RAJIV BIHANI	40000	0.17%	50000	90000	0.36%	0.32%
7	PRAKASH GADLA	Non Promoter	PRAKASH GADLA	50000	0.21%	50000	100000	0.40%	0.35%
8	K VARSHA	Non Promoter	K VARSHA	0	0.00%	50000	50000	0.20%	0.18%
9	VIJAYA SURESH NIMBALE	Non Promoter	VIJAYA SURESH NIMBALE	0	0.00%	25000	25000	0.10%	0.09%
10	PRASANTH SOWMITHRY BRUNDAVANAM	Non Promoter	PRASANTH SOWMITHRY BRUNDAVANAM	0	0.00%	25000	25000	0.10%	0.09%
11	T PRAVEEN KUMAR	Non Promoter	T PRAVEEN KUMAR	50245	0.21%	115000	165245	0.66%	0.58%
12	ALLADI PRAVEEN	Non Promoter	ALLADI PRAVEEN	42041	0.18%	50000	92041	0.37%	0.32%
13	GANGADHAR KATHURI	Non Promoter	GANGADHAR KATHURI	0	0.00%	10000	10000	0.04%	0.04%

14	RAJENDER BELIDE	Non Promoter	RAJENDER BELIDE	50000	0.21%	100000	150000	0.60%	0.53%
15	BELIDE VIJAYALAKSHMI	Non Promoter	BELIDE VIJAYALAKSHMI	50000	0.21%	100000	150000	0.60%	0.53%
16	VENKATRAMANA MANUSANI	Non Promoter	VENKATRAMANA MANUSANI	200000	0.84%	50000	250000	1.00%	0.88%
17	MANUSANI JALAJALAXMI	Non Promoter	MANUSANI JALAJALAXMI	100000	0.42%	50000	150000	0.60%	0.53%
18	PALLAPOTHU SIVAKRISHNA	Non Promoter	PALLAPOTHU SIVAKRISHNA	75000	0.31%	25000	100000	0.40%	0.35%

*\* As on 29<sup>th</sup> May, 2026*

**13. The Current and Proposed status of the allottees post the preferential issue namely, promoter or non-promoter:**

Sr. No.	Name of the Proposed Allottees	Current status of the allottees namely promoter or non-promoter	Proposed status of the allottees post the preferential issue namely promoter or non-promoter
1	SAKSHI MALANI	Non Promoter	Non Promoter
2	PEDDI SRIDHAR	Non Promoter	Non Promoter
3	PALAKURTHI RAKESH	Non Promoter	Non Promoter
4	RAHUL INNANI	Non Promoter	Non Promoter
5	SUMAN RAJIV BIHANI	Non Promoter	Non Promoter
6	VEDANT RAJIV BIHANI	Non Promoter	Non Promoter
7	PRAKASH GADLA	Non Promoter	Non Promoter
8	K VARSHA	Non Promoter	Non Promoter
9	VIJAYA SURESH NIMBALE	Non Promoter	Non Promoter
10	PRASANTH SOWMITHRY BRUNDAVANAM	Non Promoter	Non Promoter
11	T PRAVEEN KUMAR	Non Promoter	Non Promoter
12	ALLADI PRAVEEN	Non Promoter	Non Promoter
13	GANGADHAR KATHURI	Non Promoter	Non Promoter
14	RAJENDER BELIDE	Non Promoter	Non Promoter
15	BELIDE VIJAYALAKSHMI	Non Promoter	Non Promoter
16	VENKATRAMANA MANUSANI	Non Promoter	Non Promoter

17	MANUSANI JALAJA LAXMI	Non Promoter	Non Promoter
18	PALLAPOTHU SIVAKRISHNA	Non Promoter	Non Promoter

**14. The number of persons to whom allotment through preferential issue have already been made during the year in terms of number of securities as well as price:**

During the period from 1<sup>st</sup> April 2026 till the date of this notice, the Company has made Preferential Allotment as follows:

- i. 28,10,000 Equity Shares pursuant to conversion of warrants to 14 allottees belonging to Promoter/ Promoter Group and Non Promoters category of the Company at an Issue Price of Rs. 20/- each (including a premium of Rs. 10/- each) on 29<sup>th</sup> May, 2026.

However, the Company will ensure that the number of persons to whom allotment on preferential basis will be made during the financial year 2026-27 will not exceed the limit specified in the Act and rules made thereunder.

**15. The justification for the allotment proposed to be made for consideration other than cash together with valuation report of the Registered Valuer:** Not Applicable, as the proposed allotment is made for Cash consideration.

**16. Undertakings:**

- i. The Issuer Company undertakes that they shall recompute the price of the specified securities in terms of the provision of SEBI (ICDR) Regulations, 2018, as amended where it is required to do so.
- ii. The Issuer Company undertakes that if the amount payable on account of the re-computation of price is not paid within the time stipulated in terms of the provision of SEBI (ICDR) Regulations, 2018, the specified securities shall continue to be locked-in till the time such amount is paid by the allottees.

**17. Disclosure as specified under Regulation 163(1)(i) of SEBI(ICDR) Regulations 2018**

Disclosure is not applicable in the present case as neither the Proposed Allottees, the beneficial owners of Proposed Allottees nor the Company, its promoters and directors are wilful defaulters or fraudulent borrowers.

**18. Name and the address of Valuer who performed valuation-** Not Applicable

**19. Practicing Company Secretary' Certificate:**

A copy of the certificate from Mr. Bharat Khaniwal, (Membership No. ACS-29035), Proprietor of M/s. Bharat Khaniwal & Co., Practicing Company Secretary certifying that the Preferential Issue is being made in accordance with the requirements of Chapter V of SEBI (ICDR) Regulations, 2018 shall be placed before the shareholders at their proposed Extra Ordinary General Meeting and the same shall be available for inspection by the members at the Registered Office of the Company between 11:00 AM and 5:00 PM on all working days between Monday to Friday from the date of dispatch/ email of the EGM Notice till 01<sup>st</sup> July, 2026. This certificate is also placed on the website of the Company [www.novelixpharma.com](http://www.novelixpharma.com) under "Investor-Relations" tab and can be accessed through the following link: [https://novelixpharma.com/wp-content/uploads/2026/06/PCS-Certificate-Compliance-of-SEBI-ICDR\\_F.pdf](https://novelixpharma.com/wp-content/uploads/2026/06/PCS-Certificate-Compliance-of-SEBI-ICDR_F.pdf)

**20. Lock-in period**

The aforesaid allotment of Equity Shares on a preferential basis shall be locked in as per Regulation 167 of Chapter V of the SEBI (ICDR) Regulations, 2018, as amended. The entire pre-preferential allotment shareholding of the allottees, if any, shall be locked-in as per Regulation 167 (6) of Chapter V of the SEBI (ICDR) Regulations, 2018.

**21. Material Terms of Issue of Equity Shares**

Issue and allotment of 12,00,000 Equity Shares at a price of Rs. 57/- per share (Face Value of Rs. 10/- per share and Premium Rs. 47/- per share) on preferential allotment basis for cash consideration. The Equity Shares allotted in terms of this resolution shall rank pari-passu with the existing equity shares of the Company in all respects.

**22. Disclosure pursuant to the provisions of Schedule VI of SEBI (ICDR) Regulations 2018:**

It is hereby declared that neither the Proposed Allottees, the beneficial owners of Proposed Allottees, nor the Company, its promoters and directors are wilful defaulters or fraudulent borrowers as defined under SEBI (ICDR) Regulations, 2018 and neither the Proposed Allottees, the beneficial owners of Proposed Allottees, nor the Company, its directors and promoters are fugitive economic offender as defined under SEBI (ICDR) Regulations, 2018 and hence providing disclosures specified in Schedule VI of SEBI (ICDR) Regulations 2018 does not arise.

**23. Particulars of the offer, Kinds of Securities Offered, Price of the Securities Offered including date of passing of Board resolution:** Issue of 12,00,000 Equity Shares of Face Value of Rs.10/- each at an issue price of Rs. 57/- each including premium of Rs. 47/- each on preferential basis for Cash consideration.

Date of passing Board Resolution for aforesaid Preferential Issue is 04<sup>th</sup> June, 2026.

**24. Amount which the company intends to raise by way of such securities:**

The Company intends to raise Rs. 6,84,00,000/- by way of Preferential Issue of 12,00,000 Equity Shares.

**25. Contribution being made by the promoters or directors either as part of the offer or separately in furtherance of objects:** Nil

**26. Principle terms of assets charged as securities:** Not Applicable

**27. Interest of the Promoters/ Directors:**

None of Directors, Promoter / Promoter Group, Key Managerial Personnel and their relatives are in any way, directly or indirectly concerned or interested, financially or otherwise, in the proposed Special Resolution under Item No. 1 except to the extent of their shareholding, if any.

Accordingly, the Board of Directors of your Company recommend the Resolution set out in Item No. 1 of this Notice for the approval of the Members by way of passing a Special Resolution.

**By the order of the Board of Directors  
For Novelix Pharmaceuticals Limited**

**Date: 04<sup>th</sup> June, 2026  
Place: Hyderabad**

**Sd/-  
Venkateshwarlu Pulluru  
(Whole Time Director)  
DIN: 02076871**